His scientific interests lie mostly in Pharmacology, Internal medicine, Endocrinology, Neuroscience and Receptor. His studies in Pharmacology integrate themes in fields like Antagonist, Receptor antagonist, Lisuride, Bifeprunox and Citalopram. His study involves Agonist, Serotonin, Dopamine, 5-HT receptor and Serotonergic, a branch of Internal medicine.
His research in Agonist focuses on subjects like Agomelatine, which are connected to 5-HT2C receptor. His Endocrinology research is multidisciplinary, relying on both Flesinoxan, Inverse agonist and WAY-100,635. His work deals with themes such as Schizophrenia and Monoaminergic, which intersect with Neuroscience.
Mark J. Millan focuses on Pharmacology, Endocrinology, Internal medicine, Receptor and Stereochemistry. His Pharmacology research includes elements of Agonist, Antagonist, Partial agonist, 5-HT receptor and Antidepressant. Mark J. Millan has included themes like Receptor antagonist and Serotonergic, Serotonin in his Endocrinology study.
Apomorphine, Circadian rhythm, Neurotransmitter, Raclopride and Anxiolytic are subfields of Internal medicine in which his conducts study. His Receptor study typically links adjacent topics like Neuroscience. His work is dedicated to discovering how Stereochemistry, Alkyl are connected with Ring and Diastereomer and other disciplines.
His primary areas of investigation include Neuroscience, Internal medicine, Endocrinology, Pharmacology and Receptor. The study incorporates disciplines such as Glutamate receptor and Glutamatergic in addition to Neuroscience. He works mostly in the field of Endocrinology, limiting it down to topics relating to 5-HT receptor and, in certain cases, Agomelatine, as a part of the same area of interest.
His work carried out in the field of Pharmacology brings together such families of science as Antidepressant, Agonist, Dizocilpine, Antagonist and Serotonergic. His Agonist research integrates issues from Melatonergic and Reuptake. His Receptor research incorporates themes from Schizophrenia and Signal transduction, Cell biology.
Mark J. Millan mostly deals with Neuroscience, Receptor, Psychiatry, Dopamine and Dopamine receptor D3. His Prefrontal cortex study, which is part of a larger body of work in Neuroscience, is frequently linked to Piwi-interacting RNA, bridging the gap between disciplines. His Receptor study combines topics from a wide range of disciplines, such as Endocrinology and Cell biology.
His Endocrinology study combines topics in areas such as Protein kinase B and Nicotine. Mark J. Millan interconnects Pramipexole, Blockade and Ropinirole in the investigation of issues within Dopamine receptor D3. His work on Antagonist, Serotonin, Mecamylamine and Nicotinic agonist as part of general Internal medicine study is frequently linked to Methyllycaconitine, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Descending control of pain.
Mark J. Millan.
Progress in Neurobiology (2002)
The induction of pain: an integrative review
Mark J. Millan.
Progress in Neurobiology (1999)
The neurobiology and control of anxious states
Mark J. Millan.
Progress in Neurobiology (2003)
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
Mark J. Millan;Yves Agid;Martin Brüne;Edward T. Bullmore.
Nature Reviews Drug Discovery (2012)
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
Mark J. Millan.
Pharmacology & Therapeutics (2006)
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
Mark J. Millan;Alain Gobert;Françoise Lejeune;Anne Dekeyne.
Journal of Pharmacology and Experimental Therapeutics (2003)
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes
Mark J. Millan;Lisa Maiofiss;Didier Cussac;Valérie Audinot.
Journal of Pharmacology and Experimental Therapeutics (2002)
Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
Alain Gobert;Jean‐Michel Rivet;Françoise Lejeune;Adrian Newman‐Tancredi.
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
Christian de Bodinat;Béatrice Guardiola-Lemaitre;Elisabeth Mocaër;Pierre Renard.
Nature Reviews Drug Discovery (2010)
Altering the course of schizophrenia: progress and perspectives
Mark J. Millan;Annie Andrieux;George Bartzokis;Kristin Cadenhead.
Nature Reviews Drug Discovery (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: